CM313 for relapsed or refractory aplastic anemia
Part of Blood & lymphatic clinical trials.
This study tests a new medicine called CM313 for people with aplastic anemia that has returned or not responded to other treatments. It aims to see if CM313 can help improve blood cell counts.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with aplastic anemia that didn't get better with treatment or came back
- You are 18 years or older
- You are generally able to take care of yourself (ECOG score 0-2)
- You haven't had treatment with a drug called anti-CD38 (like daratumumab)
- You are not allergic to any part of the study drug
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new antibody drug (anti-CD38) for people with severe aplastic anemia that has not responded to or has come back after standard treatments. The goal is to see if this drug can help improve blood counts when other options have failed.
This trial tests if daratumumab, a targeted antibody therapy, can help patients with aplastic anemia that hasn't improved after standard treatments. It's for adults who cannot or choose not to have a stem cell transplant.
This study tests an experimental cell therapy called CK0801 for people with aplastic anemia who still need blood transfusions despite prior treatment. The goal is to see if it can help your bone marrow recover and reduce transfusion needs.
This trial tests a drug called romiplostim (Nplate) for patients whose aplastic anemia—a rare blood disorder where the bone marrow stops making enough blood cells—didn't improve after cancer treatment and hasn't responded to other medications. The drug may help your bone marrow produce more blood cells.
This trial tests a new drug called CM313 to see if it can help people whose platelet transfusions stop working. It is for adults who need platelet transfusions and have developed antibodies against them.
This trial tests a new treatment called CD7 car-t cells (rd13-02) for people with severe aplastic anemia that has not responded to standard therapy or has come back. The goal is to see if this therapy can help restore normal blood cell production.
Hear when a new Aplastic Anemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.